Centrum Medyczne Kermed Renata Bijata-Bronisz I Ewa Kowalinska Sp. j.

The site is conducting extensive research on atherosclerotic cardiovascular disease, heart failure, hypertension, and related metabolic risk factors, aiming to test new therapies that lower major adverse cardiovascular events and improve cardiac function.

• Evaluating novel agents to reduce major adverse cardiovascular events
• Assessing treatments for heart failure with preserved ejection fraction
• Investigating lipid‑lowering therapies for hypertriglyceridemia
• Studying weight‑management drugs for obesity‑related cardiovascular risk

Among the 46 active trials, a large share involve cardiovascular endpoints, with 22 investigators contributing to this therapeutic focus.

Research at the centre targets inflammatory bowel disease (Crohn’s disease and ulcerative colitis), celiac disease, and gastro‑esophageal reflux‑related erosive esophagitis, seeking to improve remission rates and mucosal healing through innovative drugs.

• Induction and maintenance strategies for inflammatory bowel disease
• Targeted biologics aiming for mucosal healing in Crohn’s disease
• Evaluating novel agents for celiac disease symptom control
• Comparing acid‑suppression therapies for erosive esophagitis

Digestive‑system trials represent a substantial portion of the programme, reflecting the site’s commitment to advancing gastrointestinal health.

The institution explores treatments for immune‑mediated conditions such as atopic dermatitis, allergic rhinitis, asthma, and chronic rhinosinusitis with nasal polyps, focusing on safety and clinical effectiveness of biologics and immunotherapies.

• Testing subcutaneous immunotherapy for house‑dust‑mite allergy
• Assessing biologics for severe atopic dermatitis
• Evaluating monoclonal antibodies for nasal polyp reduction
• Investigating immune‑modulating agents across multiple autoimmune disorders

Immune‑system research engages many of the 22 investigators and contributes to the diverse therapeutic portfolio of the centre.

Studies address obesity, overweight, type 2 diabetes, and severe hypertriglyceridemia, with trials designed to evaluate weight‑loss efficacy, glycaemic control, and lipid‑lowering outcomes.

• Exploring weight‑loss medications for obesity management
• Studying glucose‑lowering agents in type 2 diabetes
• Assessing triglyceride‑lowering therapies for severe hypertriglyceridemia
• Investigating metabolic benefits of novel peptide therapeutics

Metabolic‑disease trials form a key segment of the centre’s clinical activity, supporting patients with cardio‑metabolic risk profiles.

The centre conducts research on chronic rhinosinusitis with nasal polyps, allergic rhinitis, and related ENT conditions, aiming to improve symptom scores and anatomical outcomes through targeted biologics.

• Evaluating monoclonal antibodies for nasal polyp burden reduction
• Testing nasal symptom scores in response to targeted therapy
• Studying combination treatments for allergic rhinitis with or without asthma
• Monitoring quality‑of‑life outcomes in ENT disorders

Otorhinolaryngologic investigations complement the broader immune‑system program and are integrated into the overall trial portfolio.

Clinical work focuses on chronic obstructive pulmonary disease (COPD) and severe asthma, evaluating novel inhaled and systemic agents to reduce exacerbations and improve lung function.

• Assessing new inhaled therapies for COPD exacerbation reduction
• Comparing efficacy of anti‑inflammatory agents in severe COPD
• Investigating lung‑function improvements with biologic treatments
• Measuring symptom relief and health‑status gains in chronic respiratory disease

Respiratory‑tract trials contribute to the centre’s multidisciplinary approach, engaging several of the 22 investigators.

Research targets moderate‑to‑severe atopic dermatitis and related eczema, using both systemic biologics and topical candidates to achieve meaningful reductions in disease severity.

• Testing new systemic agents for atopic dermatitis
• Measuring EASI score improvements with investigational drugs
• Comparing efficacy of different biologics for skin inflammation
• Evaluating safety profiles in chronic eczema treatment

Skin‑focused studies are a vibrant part of the site’s trial landscape, reflecting patient demand for effective dermatologic therapies.

The centre also investigates fundamental immune system phenomena, characterizing biomarkers and cytokine pathways to personalize therapy across the various disease areas.

• Characterizing immune response pathways in inflammatory diseases
• Analyzing biomarkers for treatment response prediction
• Studying cytokine modulation across multiple trials
• Integrating immunophenotyping to personalize therapeutic choices

These mechanistic studies underpin many of the therapeutic programs, enhancing the scientific depth of the clinical research conducted at the site.